The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
We will address the hypothesis that refractory ascites and Type 2 hepatorenal syndrome are
mediated in part by diminished circulatory volume and that treatment with midodrine,
octreotide and albumin can improve renal and patient outcomes by restoring effective
circulating volume and systemic perfusion.
Our primary objective is to assess change in creatinine clearance using inulin. We will
enroll 15 patients with Type 2 hepatorenal syndrome or refractory ascites once inclusion and
exclusion criteria are satisfied. They will be treated for 1 month with octreotide LAR,
albumin and midodrine. Renal, serum and neurohormonal parameters will be measured before,
during, and after initiation of drug and compared.